Takeda thought the same thing about it's CX-601 (Darvadstrocel) cells (superiority they said) but the Admire-CD-II trial demonstrated otherwise when compared with Remestemcel-L's Complex Perianal Fistulas and Crohn's Disease results that I have seen thus far ... @reginaldp and @Wilba32 have posted Remestemcel-L's results on here previously - I am sure they can post them again as I don't have time to search at present
https://clinicaltrials.gov/study/NCT03279081?intr=Cx601&rank=2
...... and of course Takeda are happy to pay Mesoblast royalties to boot for patent infringement via a licensing agreement in the interim .... perhaps Mesoblast's patent lawyers actually do know what they are doing - just sayin'
Takeda thought the same thing about it's CX-601 (Darvadstrocel)...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
0.005(0.34%) |
Mkt cap ! $1.649B | |||
| Open | High | Low | Value | Volume |
| $1.46 | $1.49 | $1.44 | $1.968M | 1.353M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 8911 | $1.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 16481 | 5 |
View Market Depth
| Last trade - 12.42pm 21/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |